Spyre Therapeutics
SYRE
SYRE
129 hedge funds and large institutions have $953M invested in Spyre Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 63 increasing their positions, 26 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
129
Holders Change
–
Holders Change %
0%
% of All Funds
1.73%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
18
Increased
63
Reduced
26
Closed
17
Calls
$1.05M
Puts
$603K
Net Calls
+$446K
Net Calls Change
+$628K
Top Buyers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$17.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$9.38M |
| 4 |
BlackRock
New York
|
+$6.51M |
| 5 |
Morgan Stanley
New York
|
+$5.02M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$15.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$11.7M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.46M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.84M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.89M |
